Levodopa

FosB proto-oncogene, AP-1 transcription factor subunit ; Rattus norvegicus







23 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33707771 Striatal ΔFosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats. 2021 Dec 2
2 32387398 Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats. 2020 Aug 2
3 30645726 Differential Expression of Striatal ΔFosB mRNA and FosB mRNA After Different Levodopa Treatment Regimens in a Rat Model of Parkinson's Disease. 2019 Apr 12
4 29968767 Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats. 2018 Jul 3 2
5 28256089 Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease. 2017 Apr 1
6 25146322 Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia. 2016 Mar 1 7
7 25442003 Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia. 2016 Mar 1 2
8 26997328 Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats. 2016 Mar 21 1
9 25196732 Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. 2015 Feb 1
10 25787808 Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats. 2015 Aug 1
11 25896846 Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. 2015 Apr 21 1
12 23428503 Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression. 2013 Apr 29 1
13 21129389 BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. 2011 Mar 2
14 21507338 Differential expression of FosB, c-Fos, and Zif268 in forebrain regions after acute or chronic L-DOPA treatment in a rat model of Parkinson's disease. 2011 Jun 1 3
15 20505100 Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. 2010 May 26 3
16 18952677 Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. 2008 Dec 1
17 17055656 Expression pattern of JunD after acute or chronic L-DOPA treatment: comparison with deltaFosB. 2007 Jan 5 1
18 17329435 High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease. 2007 Feb 28 2
19 15056471 Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). 2004 Apr 2
20 12373525 Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. 2002 1
21 11683909 Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. 2001 Oct 3
22 10579213 Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. 1999 8
23 10600402 Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. 1999 Dec 3